What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?

被引:23
作者
Alexander, Marina R. [1 ]
Ringe, Rajesh [1 ]
Sanders, Rogier W. [1 ,2 ]
Voss, James E. [3 ,4 ,5 ]
Moore, John P. [1 ]
Klasse, Per Johan [1 ]
机构
[1] Cornell Univ, Weill Cornell Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA
[2] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands
[3] Scripps Res Inst, Int AIDS Vaccine Initiat Neutralizing Antibody Ct, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA
[4] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Design, La Jolla, CA 92037 USA
[5] Ragon Inst MGH MIT & Harvard, Charlestown, MA USA
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODIES; LINKED-IMMUNOSORBENT-ASSAY; CORECEPTOR-BINDING-SITE; NEUTRALIZING ACTIVITY; CD4; BINDING; NONNEUTRALIZING ANTIBODIES; CONFORMATIONAL EPITOPE; TRANSMEMBRANE PROTEIN; DISTINGUISHES PRIMARY;
D O I
10.1128/JVI.00320-15
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
When HIV-1 vaccine candidates that include soluble envelope glycoproteins (Env) are tested in humans and other species, the resulting antibody responses to Env are sifted for correlates of protection or risk. One frequently used assay measures the reduction in antibody binding to Env antigens by an added chaotrope (such as thiocyanate). Based on that assay, an avidity index was devised for assessing the affinity maturation of antibodies of unknown concentration in polyclonal sera. Since a high avidity index was linked to protection in animal models of HIV-1 infection, it has become a criterion for evaluating antibody responses to vaccine candidates. But what does the assay measure and what does an avidity index mean? Here, we have used a panel of monoclonal antibodies to well-defined epitopes on Env (gp120, gp41, and SOSIP. 664 trimers) to explore how the chaotrope acts. We conclude that the chaotrope sensitivity of antibody binding to Env depends on several properties of the epitopes (continuity versus tertiary-and quaternary-structural dependence) and that the avidity index has no simple relationship to antibody affinity for functional Env spikes on virions. We show that the binding of broadly neutralizing antibodies against quaternary-structural epitopes is particularly sensitive to chaotrope treatment, whereas antibody binding to epitopes in variable loops and to nonneutralization epitopes in gp41 is generally resistant. As a result of such biases, the avidity index may at best be a mere surrogate for undefined antibody or other immune responses that correlate weakly with protection. IMPORTANCE An effective HIV-1 vaccine is an important goal. Such a vaccine will probably need to induce antibodies that neutralize typically transmitted variants of HIV-1, preventing them from infecting target cells. Vaccine candidates have so far failed to induce such antibody responses, although some do protect weakly against infection in animals and, possibly, humans. In the search for responses associated with protection, an avidity assay based on chemical disruption is often used to measure the strength of antibody binding. We have analyzed this assay mechanistically and found that the epitope specificity of an antibody has a greater influence on the outcome than does its affinity. As a result, the avidity assay is biased toward the detection of some antibody specificities while disfavoring others. We conclude that the assay may yield merely indirect correlations with weak protection, specifically when Env vaccination has failed to induce broad neutralizing responses.
引用
收藏
页码:5981 / 5995
页数:15
相关论文
共 108 条
  • [1] Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 Infection
    Acharya, Priyamvada
    Tolbert, William D.
    Gohain, Neelakshi
    Wu, Xueji
    Yu, Lei
    Liu, Tongyun
    Huang, Wensheng
    Huang, Chih-chin
    Do Kwon, Young
    Louder, Robert K.
    Luongo, Timothy S.
    McLellan, Jason S.
    Pancera, Marie
    Yang, Yongping
    Zhang, Baoshan
    Flinko, Robin
    Foulke, James S., Jr.
    Sajadi, Mohammad M.
    Kamin-Lewis, Roberta
    Robinson, James E.
    Martin, Loic
    Kwong, Peter D.
    Guan, Yongjun
    DeVico, Anthony L.
    Lewis, George K.
    Pazgier, Marzena
    [J]. JOURNAL OF VIROLOGY, 2014, 88 (21) : 12895 - 12906
  • [2] ANTIGENIC STRUCTURES OF PROTEINS - THEIR DETERMINATION HAS REVEALED IMPORTANT ASPECTS OF IMMUNE RECOGNITION AND GENERATED STRATEGIES FOR SYNTHETIC MIMICKING OF PROTEIN-BINDING SITES
    ATASSI, MZ
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1984, 145 (01): : 1 - 20
  • [3] IgG Subclass Profiles in Infected HIV Type 1 Controllers and Chronic Progressors and in Uninfected Recipients of Env Vaccines
    Banerjee, Kaustuv
    Klasse, P. J.
    Sanders, Rogier W.
    Pereyra, Florencia
    Michael, Elizabeth
    Lu, Min
    Walker, Bruce D.
    Moore, John P.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2010, 26 (04) : 445 - 458
  • [4] Structure of antibody f425-b4e8 in complex with a v3 peptide reveals a new binding mode for HIV-1 neutralization
    Bell, Christian H.
    Pantophlet, Ralph
    Schiefner, Andre
    Cavacini, Lisa A.
    Stanfield, Robyn L.
    Burton, Dennis R.
    Wilson, Ian A.
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2008, 375 (04) : 969 - 978
  • [5] THE ANTIGENIC STRUCTURE OF PROTEINS - A REAPPRAISAL
    BENJAMIN, DC
    BERZOFSKY, JA
    EAST, IJ
    GURD, FRN
    HANNUM, C
    LEACH, SJ
    MARGOLIASH, E
    MICHAEL, JG
    MILLER, A
    PRAGER, EM
    REICHLIN, M
    SERCARZ, EE
    SMITHGILL, SJ
    TODD, PE
    WILSON, AC
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1984, 2 : 67 - 101
  • [6] INTRINSIC AND EXTRINSIC FACTORS IN PROTEIN ANTIGENIC STRUCTURE
    BERZOFSKY, JA
    [J]. SCIENCE, 1985, 229 (4717) : 932 - 940
  • [7] An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1
    Binley, JM
    Arshad, H
    Fouts, TR
    Moore, JP
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (12) : 1007 - 1015
  • [8] Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family
    Bonsignori, Mattia
    Pollara, Justin
    Moody, M. Anthony
    Alpert, Michael D.
    Chen, Xi
    Hwang, Kwan-Ki
    Gilbert, Peter B.
    Huang, Ying
    Gurley, Thaddeus C.
    Kozink, Daniel M.
    Marshall, Dawn J.
    Whitesides, John F.
    Tsao, Chun-Yen
    Kaewkungwal, Jaranit
    Nitayaphan, Sorachai
    Pitisuttithum, Punnee
    Rerks-Ngarm, Supachai
    Kim, Jerome H.
    Michael, Nelson L.
    Tomaras, Georgia D.
    Montefiori, David C.
    Lewis, George K.
    DeVico, Anthony
    Evans, David T.
    Ferrari, Guido
    Liao, Hua-Xin
    Haynes, Barton F.
    [J]. JOURNAL OF VIROLOGY, 2012, 86 (21) : 11521 - 11532
  • [9] A Blueprint for HIV Vaccine Discovery
    Burton, Dennis R.
    Ahmed, Rafi
    Barouch, Dan H.
    Butera, Salvatore T.
    Crotty, Shane
    Godzik, Adam
    Kaufmann, Daniel E.
    McElrath, M. Juliana
    Nussenzweig, Michel C.
    Pulendran, Bali
    Scanlan, Chris N.
    Schief, William R.
    Silvestri, Guido
    Streeck, Hendrik
    Walker, Bruce D.
    Walker, Laura M.
    Ward, Andrew B.
    Wilson, Ian A.
    Wyatt, Richard
    [J]. CELL HOST & MICROBE, 2012, 12 (04) : 396 - 407
  • [10] Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody
    Burton, Dennis R.
    Hessell, Ann J.
    Keele, Brandon F.
    Klasse, Per Johan
    Ketas, Thomas A.
    Moldt, Brian
    Dunlop, D. Cameron
    Poignard, Pascal
    Doyle, Lara A.
    Cavacini, Lisa
    Veazey, Ronald S.
    Moore, John P.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (27) : 11181 - 11186